To evaluate the health outcomes of daratumumab in monotherapy in the treatment of adult patients with relapsed refractory multiple myeloma (RRMM), who have previously received a proteasome inhibitor and an immunomodulatory agent and who have experienced disease progression in the last treatment.

C. Alarcón-Payer¹, J.E. Martínez-De la Plata¹, S. Cano Domínguez¹, M.E. Clavero Sánchez², R. Ríos Tamayo², M. Jurado Chacón², A. Jiménez Morales¹
Servicio de Farmacia. Hospital Universitario Virgen de las Nieves. Granada¹
Servicio de Hematología y Hemoterapia. Hospital Universitario Virgen de las Nieves. Granada²
e-mail: carolina.alarcon.sspa@juntadeandalucia.es

EVALUATION OF HEALTH OUTCOMES OF DARATUMUMAB IN MONOTHERAPY IN ADULT PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA

PURPOSE

To evaluate the health outcomes of daratumumab in monotherapy in the treatment of adult patients with relapsed refractory multiple myeloma (RRMM), who have previously received a proteasome inhibitor and an immunomodulatory agent and who have experienced disease progression in the last treatment.

MATERIAL AND METHODS

Prospective observational study conducted over a period of 2 years in a third level hospital. Eleven patients diagnosed with RRMM have been analyzed. To evaluate the measurement of health outcomes, the following variables were measured: age, sex, number of previous lines, daratumumab cycles received, progression-free survival (PFS) and adverse reactions.

RESULTS

Eleven RRMM cases were analyzed (80%: men; 20%: women): The mean age was 63 years.
50% → Daratumumab in monotherapy in 3rd line
30% → Daratumumab in monotherapy in 4rd line
20% → Daratumumab in monotherapy in 6rd and 7rd line
The mean number of daratumab cycles → 7 except for one patient who has now completed cycle 20
The median PFS (months) → 4
Adverse reactions → nausea and vomiting (20%)

CONCLUSION

- Health outcomes of daratumumab in monotherapy for the treatment of patients with RRMM are similar to those published in the combined trial gene 501 and SIRIUS.
- According to recent publications, daratumumab is likely to be more effective in combination with other drugs.
- Daratumumab is well tolerated in most patients and is therefore considered a safe treatment.